MS-N171 · Exercise and rehabilitation · stage I–III breast-cancer survivors reporting cognitive difficulty
Evidence at a glance
- Question: Does a remotely coached aerobic-exercise program improve cognition after breast-cancer treatment?
- Finding: No advantage was found for the two primary cognitive outcomes; attention and short-term memory signals were secondary.
- Evidence label: Mixed randomized evidence; primary outcomes negative
- Benefit: Physical activity increased, with exploratory domain-specific cognitive signals.
- Certainty: Moderate for no effect on self-reported cognition and processing speed; low for secondary attention and memory effects.
- Risk: Safety outcomes were not reported in the accessible extract.
- Cancer-control boundary: The study assessed cognition and activity, not recurrence or survival.
What was studied
The I Can! trial enrolled women aged 40 or older, within five years of stage I–III breast cancer, at least six months after active treatment, reporting cognitive difficulty and low baseline activity.
- Design and comparator: Parallel randomized trial of remotely coached aerobic exercise versus a contact-matched health-and-wellness attention control.
- Participants: 253 survivors randomized. The trial was powered for the two primary cognitive outcomes.
- Intervention: Six months of coaching and Fitbit-supported moderate-to-vigorous aerobic activity, targeting 150 minutes weekly, followed by six months of maintenance support.
- Primary outcome and follow-up: PROMIS Cognitive Abilities and NIH Toolbox processing speed at six months; 12 months was a secondary maintenance endpoint.
What the study found
Exercise increased moderate-to-vigorous activity by about five minutes per day relative to control, but did not improve self-reported cognition or processing speed at six or 12 months. Secondary attention scores favored exercise at six months (b=0.14; P=.03) and 12 months (b=0.21; P=.002), and memory favored exercise at six months only.
Negative or uncertain findings: The prespecified primary cognitive outcomes were null. The domain-specific findings were secondary, and clinically meaningful thresholds were not established for the primary measures.
Limits and applicability
Participants were selected for low activity, device access and self-reported cognitive problems. Contact-matched controls also improved, and the modest activity separation may have limited detectable effects.
Funding and conflicts: Funding and conflict disclosures were present in the journal report but were not fully extracted in this pass.
Safety context
New neurologic deficits, severe headache, focal weakness or rapidly worsening cognition require clinical assessment rather than an exercise-only response. Post-treatment cardiotoxicity, neuropathy, falls and bone health can change safe exercise intensity.
Questions for the care team
- Has cognition been evaluated for sleep, mood, medications, menopause, thyroid disease or anemia?
- Would a structured survivorship exercise referral be appropriate?
- Which outcome matters most—attention, memory, daily function or fatigue?
Primary sources
Last literature search: 29 October 2026. Record appraisal: 29 October 2026. This page is educational and does not replace individualized medical advice. Exercise prescriptions should be adapted to diagnosis, treatment, surgical restrictions, blood counts, cardiopulmonary status, neuropathy, fall risk and bone-metastasis location. Symptom or fitness improvement is not proof of tumor response, recurrence prevention or longer survival unless those outcomes were directly tested.
